Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2010 AND VI 28 AND IP 1
Results: 9
1
2
Adverse drug interactions: moving from perception to action.
- Published in:
- 2010
- By:
- Publication type:
- journal article
3
The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients.
- Published in:
- PharmacoEconomics, 2010, v. 28, n. 1, p. 23, doi. 10.2165/11313810-000000000-00000
- By:
- Publication type:
- Article
4
Should Financial Incentives be Used to Differentially Reward 'Me-Too' and Innovative Drugs?
- Published in:
- PharmacoEconomics, 2010, v. 28, n. 1, p. 1, doi. 10.2165/11318770-000000000-00000
- By:
- Publication type:
- Article
5
Erlotinib: A Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer.
- Published in:
- PharmacoEconomics, 2010, v. 28, n. 1, p. 75, doi. 10.2165/10482880-000000000-00000
- By:
- Publication type:
- Article
6
Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma.
- Published in:
- PharmacoEconomics, 2010, v. 28, n. 1, p. 35, doi. 10.2165/11314070-000000000-00000
- By:
- Publication type:
- Article
7
Adverse Drug Interactions.
- Published in:
- 2010
- By:
- Publication type:
- Opinion
8
A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing.
- Published in:
- PharmacoEconomics, 2010, v. 28, n. 1, p. 61, doi. 10.2165/11318240-000000000-00000
- By:
- Publication type:
- Article
9
Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US.
- Published in:
- PharmacoEconomics, 2010, v. 28, n. 1, p. 47, doi. 10.2165/11531440-000000000-00000
- By:
- Publication type:
- Article